

## Daftar Pustaka

1. Menkes I. Pedoman Nasional Pelayanan Kedokteran Tata Laksana Otitis Media Supuratif Kronik. *Keputusan Menteri Kesehatan Republik Indonesia*. 2018;Nomor HK.0:1-130.
2. WHO. *Chronic Suppurative Otitis Media, burden of Illness and Management Options*. (Acuin J, ed.). Geneva: WHO; 2004.
3. Helmi. *Otitis Media Supuratif Kronis Pengetahuan Dasar Terapi Medik Mastoidektomi Timpanoplasti*. Balai Penerbit FKUI; 2005.
4. Arts A, Adams M. Intratemporal and intracranial complication of otitis media. In: Johnson J, Rosen C, eds. *Bailey's Head and Neck Surgery Otolaryngology*. Lippincot William & Wilkins; 2014:2399-2409.
5. Frickmann H. Cholesteatoma ? A Potential Consequence of Chronic Middle Ear Inflammation. *Otolaryngology*. 2012;2(3).1-8
6. Olszewska E, Sudhoff H. Comparative cytokeratin distribution patterns in cholesteatoma epithelium. *Histol Histopathol*. 2007;22(1-3):37-42.
7. de Aquino JEAP, Filho NAC, de Aquino JNP. Epidemiology of middle ear and mastoid cholesteatomas. study of 1146 cases. *Braz J Otorhinolaryngol*. 2011;77(3):341-7.
8. Louw L. Acquired cholesteatoma pathogenesis: Stepwise explanations. *J Laryngol Otol*. 2010;124(6):587-93.
9. Maniu A, Harabagiu O, Schrepler MP, et al. Molecular biology of cholesteatoma. *Rom J Morphol Embryol*. 2014;55(1):7-13.
10. Kuo CL, Shiao AS, Yung M, et al. Updates and knowledge gaps in cholesteatoma research. *Biomed Res Int*. 2015;20(5):1-18
11. Bennett M, Warren F, Jackson GC, et al. Congenital Cholesteatoma: Theories, Facts, and 53 Patients. *Otolaryngol Clin North Am*. 2006;39(6):1081-94.
12. Hamed MA, Nakata S, Sayed RH, et al. Pathogenesis and bone resorption in acquired cholesteatoma: Current knowledge and future perspectives. *Clin Exp Otorhinolaryngol*. 2016;9(4):298-308.
13. Emre E. An Overview to Cytokeratin Pattern. *Acıbadem Üniversitesi Sağlık Bilimleri Dergisi*. 2015;(9):1-6.

14. Rutkowska J, Ozgirgin N, Olszewska E. Cholesteatoma Definition and Classification: A Literature Review. *J Int Adv Otol.* 2017;13(2):266-71.
15. Dornelles C, Costa SS, Meurer L, Schweiger C. Some considerations about acquired adult and pediatric cholesteatomas. *Braz J Otorhinolaryngol.* 2005;71(4):536-45.
16. Ahmed Z, Khan TZ, Rahim DU. Otogenic complications of otitis media : experience at tertiary care hospital. *Braz J Otorhinolaryngol.* 2015:49-53.
17. Rehman MUR, Hussain G. Frequency of Complications in Chronic Suppurative Otitis Media. *Eur Arch Oto-Rhino-Laryngology.* 2013;3(2):4-6.
18. Xie S, Wang X, Ren J, et al. The role of bone resorption in the etiopathogenesis of acquired middle ear cholesteatoma. *Eur Arch Oto-Rhino-Laryngology.* 2017;274(5):2071-8.
19. Kim H, Tinling SP, Chole RA. Expression Patterns of Cytokeratins in Retraction Pocket Cholesteatomas. *Eur Arch Oto-Rhino-Laryngology.* 2001;(6):1032-6.
20. Mostafa BE, El-monayeri MSE, Elfiky L, et al. Cytokeratin 16 Expression Does Not Indicate Cholesteatoma Aggressiveness. *J Hear Sci.* 2012;2(2):50-6.
21. Abdelmonem M, Mostafa O. Immunohistochemical Study of Ki67 , Pcn and P53 in Human. 2015;13(4):28-38.
22. Lessard JC, Pina-Paz S, Rotty JD, et al. Keratin 16 regulates innate immunity in response to epidermal barrier breach. *Proc Natl Acad Sci.* 2013;110(48):19537-42.
23. Kumar A. Cytokeratin : A Review on Current Concepts. *Int J Orofac Biol.* 2018;2:6-11.
24. Schweizer J, Bowden PE, Coulombe PA, et al. New consensus nomenclature for mammalian keratins. *J Cell Biol.* 2006;174(2):169-74.
25. Elango T, Thirupathi A, Subramanian S, et al. Methotrexate normalized keratinocyte activation cycle by overturning abnormal keratins as well as deregulated inflammatory mediators in psoriatic patients. *Clin Chim Acta.* 2015;451:329-37.
26. Hamed MA, Nakata S, Shiogama K, et al. Cytokeratin 13, cytokeratin 17,

- and Ki-67 expression in human acquired cholesteatoma and their correlation with its destructive capacity. *Clin Exp Otorhinolaryngol.* 2017;10(3):213-20.
27. Kim HJ, Tinling SP, Chole RA. Expression patterns of cytokeratins in cholesteatomas: evidence of increased migration and proliferation. *J Korean Med Sci.* 2002;17(3):381-8.
  28. Kwon Keeh, Kim Seojin, Kim Hjin, et al. Analysis of gene expression profiles in cholesteatoma using oligonucleotide microarray. *Acta Oto-Laryngologica*, 2006; 12(6): 691-7
  29. Wong P, Coulombe PA. Loss of keratin 6 (K6) proteins reveals a function for intermediate filaments during wound repair. *J Cell Biol.* 2003;163(2):327-37.
  30. Zarandy M. Cholesteatoma and Its Complications. In: *Diseases of the Inner Ear*. Berlin: Springer Berlin; 2010:1523-9.
  31. Kojima H, Miyazaki H, Shiwa M, et al. Molecular biological diagnosis of congenital and acquired cholesteatoma on the basis of differences in telomere length. *Laryngoscope.* 2001;111(5):867-73.
  32. Kim YH, Yoo JC, Lee JH, et al. Stage progression of congenital cholesteatoma in children. *Eur Arch Oto-Rhino-Laryngology.* 2012;269(3):833-7.
  33. Kuo CL. Etiopathogenesis of acquired cholesteatoma: Prominent theories and recent advances in biomolecular research. *Laryngoscope.* 2015;125(1):234-40.
  34. Ken K, Potsic WP. Congenital Cholesteatoma. *Curr Opin Otolaryngol Head Neck Surg.* 2004;(12):398-403.
  35. Bassiouny M, Badour N, Omran A, et al. Histopathological and immunohistochemical characteristics of acquired cholesteatoma in children and adults. *Egypt J Ear, Nose, Throat Allied Sci.* 2012;13(1):7-12.
  36. Kim HJ, Tinling SP, Chole RA. Increased proliferation and migration of epithelium in advancing experimental cholesteatomas. *Otol Neurotol.* 2002;23(6):840-4.
  37. Walker D, Shinnors MJ. Congenital Cholesteatoma. *Pediatr Ann.*

2016;45(5):e167-e170.

38. Nevoux J, Lenoir M, Roger G, et al. Childhood cholesteatoma. *Eur Ann Otorhinolaryngol Head Neck Dis.* 2010;127(4):143-50.
39. Jackler RK, Maria PLS, Varsak YK, et al. Triological Society Candidate Thesis A New Theory on the Pathogenesis of Acquired Cholesteatoma : Mucosal Traction. 2015;(8):1-14.
40. Kanemaru SI, Kikkawa Y, Omori K, et al. Bone destructive mechanisms of cholesteatoma. *Laryngoscope.* 2010;120(3):68-70.
41. Olszewska E, Wagner M, Ebmeyer MJB. Etiopathogenesis of cholesteatoma. *Eur Arch Otorhinolaryngol.* 2004;26(1):6-24
42. Nguyen KH, Suzuki H, Ohbuchi T, et al. Possible participation of acidic pH in bone resorption in middle ear cholesteatoma. *Laryngoscope.* 2014;124(1):245-50.
43. Duan L, Chen H, Gao J. The Cytoskeleton of the System. 2017:17-22.
44. Depianto D, Coulombe PA. Intermediate filaments and tissue repair. *Exp Cell Res.* 2004;301(1):68-76.
45. Juráňová J, Franková J, Ulrichová J. The role of keratinocytes in inflammation. *J Appl Biomed.* 2017;15(3):169-79.
46. Freedberg IM, Tomic-Canic M, Komine M, et al. Keratins and the keratinocyte activation cycle. *J Invest Dermatol.* 2001;116(5):633-40.
47. Chung JH, Lee SH, Park CW, et al. Expression of apoptotic vs antiapoptotic proteins in middle ear cholesteatoma. *Otolaryngol - Head Neck Surg (United States).* 2015;153(6):1024-30.
48. Klenke C, Janowski S, Borck D, et al. Identification of Novel Cholesteatoma-Related Gene Expression Signatures Using Full-Genome Microarrays. *PLoS One.* 2012;7(12):1-14
49. Dahlan S. Menggunakan rumus besar sampel secara benar. In: *Besar Sampel Dan Cara Pengambilan Sampel.* 3rd ed. Jakarta: Salemba Medika; 2013:35-72.
50. Sastroasmoro S, Ismael S. Perkiraan besar sampel. In: *Dasar Dasar Metodologi Penelitian Klinis.* 3rd ed. Jakarta: Sagung Seto; 2008:302-32.
51. Yulius S, Asroel HA, Aboet A, et al. Correlation of Matrix

- Metalloproteinase-9 (MMP-9) expression and bone destruction in Chronic Suppurative Otitis Media (CSOM) patients with cholesteatoma at Adam Malik General Hospital Medan-Indonesia. *Bali Med J.* 2018;7(1):195-7.
52. Naim R, Riedel F, Bran G, et al. Expression of  $\beta$ -catenin in external auditory canal cholesteatoma (EACC). *BioFactors.* 2003;19(3-4):189-95.
53. Fedchenko N, Reifenrath J. Different approaches for interpretation and reporting of immunohistochemistry analysis results in the bone tissue – a review. 2014:1-12.
54. Musharaf Baig M, Ajmal M, Saeed I, et al. Prevalence of Cholesteatoma and its Complications in Patients of Chronic Suppurative Otitis Media. *J Rawalpindi Med Coll.* 2011;15(1):16-7.
55. Artono, Purnami N, Rahmawati R. Biofilm bacteria plays a role in CSOM pathogenesis and has significant correlation with unsafe type CSOM. *Folia Medica Indones.* 2014;51(4):208-13.
56. Khan MA, Asaduzzaman A, Islam MT, et al. Clinical Presentation of Cholesteatoma- A Study of 50 Cases. *J Armed Forces Med Coll Bangladesh.* 2017;13(1):66-70.
57. Yamamoto K, Yaguchi Y, Kojima H. Clinical analysis of secondary acquired cholesteatoma. *Am J Otolaryngol - Head Neck Med Surg.* 2014;35(5):589-93.
58. Castle JT. Cholesteatoma Pearls: Practical Points and Update. *Head Neck Pathol.* 2018;12(3):419-29.
59. Sandeep S. How Safe is Safe Ear?: A Hospital Based Study. *Int J Sci study.* 2014;2(2):3-6.
60. Roopashree BVSTJ. Mastoid Cholesteatoma: A Result of Metaplasia. 2013;65(12):665-9.
61. Min HJ, Park CW, Jeong JH, et al. Comparative analysis of the expression of involucrin, filaggrin and cytokeratin 4, 10, 16 in cholesteatoma. *Korean J Audiol.* 2012;16(3):124-9.
62. Swanda D, Edward Y, Munilson J. Ekspresi Tumor Necrosis Factor dan Interleukin-6 Pada Kolesteatoma Penderita Otitis Media Supuratif Kronis. 2017. 37-9

63. Vitale RF, Ribeiro F de AQ. The role of tumor necrosis factor-alpha (TNF-alpha) in bone resorption present in middle ear cholesteatoma. *Rev Bras Otorrinolaringol (English ed)*. 2007;73(1):117-21.
64. Hamed M, Sayed R, Shiogama K, Nakata S, Badawy B, Tsutsumi Y. Cytokeratin expression pattern in acquired cholesteatoma versus meatal skin; an immunochemical study. *Forsch heute – Zukunft morgen*. 2018;97:70-6
65. Martin SF, Jakob T. Contact dermatitis. *Clin Basic Immunodermatology Second Ed*. 2017:411-29.

